Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest IMRIS Inc. Stories

2013-08-08 16:26:41

WINNIPEG & MINNEAPOLIS, MN, Aug. 8, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) _____________________________________________________________________ |Second Quarter 2013 Earnings|August 13, 2013 | |Release | | |____________________________|________________________________________| |Conference Call and Webcast |August 13, 5:00 pm ET |...

2013-08-08 12:25:34

Intraoperative MR imaging improves surgical vision, reduces re-operation risk in treating epilepsy, tumors, other neurological disorders MINNEAPOLIS, Aug. 8, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that a craniotomy recently performed on a five-year-old boy with epilepsy was the 500(th) neurosurgical case at Cook Children's Medical Center in Fort Worth, Texas, using its intraoperative MRI (iMRI) system. Cook Children's was...

2013-07-29 20:21:05

WINNIPEG and MINNEAPOLIS, July 29, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that Jay D. Miller, the company's current President and COO, will also become the CEO of IMRIS Inc., effective August 1, 2013.  Chairman and CEO David Graves will continue as the Chair of the Board of Directors of the Corporation. "IMRIS has grown from a single idea into a business that impacts the lives of patients every day," said David...

2013-06-26 12:32:12

Neurosurgeons say VISIUS(®) is safe, more precise tool for intraoperative imaging MINNEAPOLIS, June 26, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today reported that Le Bonheur Children's Hospital in Memphis, TN, is crediting intraoperative MRI (iMRI) within the VISIUS(®) Surgical Theatre with reducing returns to the operating room for residual tumor removal by 84 percent over 2 years. The VISIUS Surgical Theatre at Le Bonheur provides...

2013-06-19 12:27:34

Intraoperative MRI and angiography confirms retinoblastoma chemotherapy treatment MINNEAPOLIS, MN, June 19, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that Yale-New Haven Hospital, New Haven, CT, neurosurgeons are confirming effective chemotherapy delivery in treating eye cancer using intraoperative imaging within the VISIUS(®) Surgical Theatre. Selective intra-arterial chemotherapy is a growing strategy for treating...

2013-06-12 12:28:27

VISIUS(®) Surgical Theatre iMRI brings increased tumor resection and limits patient risks MINNEAPOLIS, MN, June 12, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that University Hospital Tübingen neurosurgeons in Tübingen, Germany, are reporting success toward their objectives of limiting patient risk and improving surgical precision using intraoperative MRI for brain surgery procedures in the...

2013-05-30 20:21:17

WINNIPEG, MB, May 30, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced the appointment of James Hickey to the company's board of directors effective June 1, 2013. Mr. Hickey is an experienced medical device industry executive who brings more than 25 years of experience in building, managing and leading successful medical technology companies.  He began his career with American Hospital Supply/Baxter Healthcare in 1977. ...

2013-05-30 12:28:06

First Combination of ClearPoint(®) Neuro Intervention System within VISIUS(®) Surgical Theatre to Achieve Real-Time MRI-Guided Delivery of Investigational Gene Therapy Drug Toca 511 Highlights Collaboration among Three High-Tech Healthcare Companies to Deliver Novel Therapy IRVINE, CA, May 30, 2013 /PRNewswire/ - MRI Interventions, Inc. (OTCQB:MRIC) and IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS") today announced that a surgical team at a leading U.S. neuroscience institution...

2013-05-22 16:25:26

Key patent includes claims on haptics, MR compatibility and image-guidance WINNIPEG, May 22, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced the allowance of a US patent defining the foundational technologies for its SYMBIS(TM) Surgical System - a minimally invasive and MRI-compatible microsurgical robot system. Currently under development at IMRIS, the SYMBIS Surgical System is an image-guided, micro-neurosurgery robot that will...

2013-05-02 16:28:56

WINNIPEG, May 2, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today reported its results for the first quarter of 2013.  All figures are reported in US dollars. Revenues were $8.1 million in the quarter compared with $3.5 million in the first quarter of 2012. Net loss in the first quarter was $8.4 million, largely unchanged from the first quarter of 2012. Highlights: -- Quarterly revenues increase by 131% to $8.1 million...